Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxymetazoline + ketamine
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intranasal, Topical, Oral, Intravenous, Intramuscular
01
Overview
**Oxymetazoline + ketamine** is a theoretical or compounded combination of two pharmaceuticals: oxymetazoline, a direct-acting alpha-adrenergic agonist primarily used as a topical decongestant and vasoconstrictor, and ketamine, a dissociative anesthetic that acts mainly as an NMDA receptor antagonist with additional effects on opioid and other receptors. There is no evidence of a marketed fixed-dose combination product with this exact pairing, but both drugs may be co-administered in clinical practice (for example, in certain procedural settings). If coadministered, synergy may occur due to additive effects on blood pressure and heart rate. The main clinical relevance of this combination relates to enhanced cardiovascular stimulation and the need for monitoring, rather than a uniquely developed drug indication or formulation[1][6][7][9].
- Other names
- oxymetazoline + ketamine
02
Targets
ADRA2A (α2A)ADRA2B (α2B)ADRA2C (α2C)ADRB2 (β2)NMDAR (Glutamate receptor ionotropic, NMDA)ADRA1A (α1A)
Beyond the preview
Go deeper on oxymetazoline + ketamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxymetazoline + ketamine.